RN-1701 in Large B-cell lymphoma: NCT07506668 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 16 September 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 1/2
Clinical phase
Not yet recruiting
Recruitment status
10
Planned enrollment
2028-03-30
Primary-completion proxy
Executive view
NCT07506668 evaluates RN-1701 in Large B-cell lymphoma. The disclosed sponsor is Affiliated Hospital of Nantong University, the design is Interventional, and the geographic footprint is Geography not reported. The first listed primary endpoint is Toxicity and adverse event grading after RN1701 treatment, assessed over up to 12 months after infusion.
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07506668 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Large B-cell lymphoma landscape. Drug & Asset MCP drug_fetch was queried for RN-1701, while Company & Deal Intelligence MCP organization_fetch was queried for Affiliated Hospital of Nantong University.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07506668 | RN-1701 | Phase 1/2 / Not yet recruiting | Affiliated Hospital of Nantong University | Geography not reported | Toxicity and adverse event grading after RN1701 treatment up to 12 months after infusion | 2028-03-30 |
| NCT07729397 | CD30.CAR-EBVST cell therapy(Baylor College of Medicine) | Phase 1 / Not yet recruiting | The Methodist Hospital Research Institute | United States | Incidence of Dose-Limiting Toxicities (DLTs) From initiation of lymphodepleting chemotherapy through 28 days follo… | 2030-03-31 |
| NCT07691606 | ARC-02 | Phase 1 / Recruiting | Taiho Oncology, Inc. | United States, Poland, Italy, France, Australia, Spain | Dose Escalation: Number of Participants with Dose-Limiting Toxicities (DLTs) Up to 5 years | 2029-01-01 |
| NCT07649304 | Cyclophosphamide | Phase 1 / Not yet recruiting | National Cancer Institute | Geography not reported | Ability to deliver at least 4 full cycles of glofitamab-rituximab, cyclophosphamide, doxorubicin, vincristine, and pred… Up to cycle 4 (Cycles = 21 days) | 2028-04-30 |
| NCT07638982 | Axatilimab-csfr | Phase 1 / Not yet recruiting | Northside Hospital, Inc. | United States | Determine the recommended Phase 2 dose (RP2D) of axatilimab 1 year | 2028-12-31 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07506668 is a Phase 1/2, not yet recruiting study with 10 planned participants. Allocation is N/A, masking is None (Open Label), and the intervention model is Single Group Assignment.
The primary endpoint is “Toxicity and adverse event grading after RN1701 treatment” over “up to 12 months after infusion.” The retrieved endpoint description is: all toxicities and AEs will be assessed according to the National Cancer Institute CTCAE v5.0.
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of 10 should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
5 recent result records were selected as contextual evidence for Large B-cell lymphoma. These records do not establish direct evidence for NCT07506668 unless the registration number matches.
A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circu…
Phase 2; n=46; End of Treatment Complete Response (EOT CR) Rate = 73.3 Percentage of participants (95% Confidence Interval, 58.06 - 85.40) Source: https://clinicaltrials.gov/ct2/show/results/NCT04980222
A Phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 a Long-acting Human IL-7, Post-Kymriah®, Post-Yescarta®, or Post-Breyanzi® in Sub…
Phase 1; n=17; Any TEAEs = 3 Participants ; Any TEAEs = 2 Participants Source: https://clinicaltrials.gov/ct2/show/results/NCT05075603
Ultralow-Dose Interleukin 10–Expressing Chimeric Antigen Receptor T Cells in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Phase 1; n=13; CR = 84.6 % Source: https://pubmed.ncbi.nlm.nih.gov/42490071/
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
No exact Drug & Asset MCP profile was returned for the protocol wording “RN-1701.” The report therefore avoids inferring modality, target or global development stage from the name alone.
No exact Company & Deal Intelligence profile was returned for Affiliated Hospital of Nantong University. Sponsor identity is retained from the trial protocol without adding unsupported corporate claims.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether RN-1701 is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07506668
Protocol source: https://clinicaltrials.gov/study/NCT07506668
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 16 September 2026.
RN-1701 in Large B-cell lymphoma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Toxicity and adverse event grading after RN1701 treatment and 2028-03-30 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
